Neurosteroid modulation of recombinant ionotropic glutamate receptors.
Pregnenolone sulfate (PS) is an abundant neurosteroid that can potentiate or inhibit ligand gated ion channel activity and thereby alter neuronal excitability. Whereas PS is known to inhibit kainate and AMPA responses while potentiating NMDA responses, the dependence of modulation on receptor subunit composition remains to be determined. Toward this end, the effect of PS on recombinant kainate (GluR6), AMPA (GluR1 or GluR3), and NMDA (NR1(100)+NR2A) receptors was characterized electrophysiologically with respect to efficacy and potency of modulation. With Xenopus oocytes expressing GluR1, GluR3 or GluR6 receptors, PS reduces the efficacy of kainate without affecting its potency, indicative of a noncompetitive mechanism of action. Conversely, with oocytes expressing NR1(100)+NR2A subunits, PS enhances the efficacy of NMDA without affecting its potency. Whereas the modulatory efficacy, but not the potency, of PS is increased two-fold by co-injection of NR1(100)+NR2A cRNAs as compared with NR1(100) cRNA alone, there is little or no effect of the NR2A subunit on efficacy or potency of pregnanolone (or epipregnanolone) sulfate as an inhibitor of the NMDA response. This suggests that the NR2A subunit controls the efficacy of neurosteroid enhancement, but not inhibition, which is consistent with our previous finding that potentiating and inhibitory steroids act at distinct sites on the NMDA receptor. This represents a first step towards understanding the role of subunit composition in determining neurosteroid modulation of ionotropic glutamate receptor function.
Yaghoubi
N
N
Laboratory of Molecular Neurobiology, Department of Pharmacology, Boston University School of Medicine, 715 Albany Street, Boston, MA 02118, USA.
Malayev
A
A
Russek
S J
SJ
Gibbs
T T
TT
Farb
D H
DH
D000305:Adrenal Cortex Hormones; D000818:Animals; D004305:Dose-Response Relationship, Drug; D007608:Kainic Acid / Q000037:antagonists & inhibitors / Q000494:pharmacology; D008845:Microinjections; D018377:Neurotransmitter Agents / Q000494:pharmacology* / Q000502:physiology; D009865:Oocytes / Q000166:cytology / Q000187:drug effects; D011284:Pregnenolone / Q000494:pharmacology; D018075:RNA, Complementary / Q000008:administration & dosage / Q000187:drug effects / Q000494:pharmacology; D051381:Rats; D018091:Receptors, AMPA / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D018092:Kainic Acid Receptors / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D016194:Receptors, N-Methyl-D-Aspartate / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D011994:Recombinant Proteins / Q000187:drug effects / Q000378:metabolism*; D014981:Xenopus; D000097806:GluK2 Kainate Receptor
D000305:Adrenal Cortex Hormones; D007608:Kainic Acid; D018377:Neurotransmitter Agents; D011284:Pregnenolone; D018075:RNA, Complementary; D018091:Receptors, AMPA; D018092:Kainic Acid Receptors; D016194:Receptors, N-Methyl-D-Aspartate; D011994:Recombinant Proteins; D000097806:GluK2 Kainate Receptor; C104723:glutamate receptor ionotropic, AMPA 3; C018370:pregnenolone sulfate